|Tested species reactivity||Human|
|Host / Isotype||Rabbit / IgG|
|Immunogen||Synthetic peptide from C-terminus of human c-Met protein.|
|Purification||Antigen affinity chromatography|
|Storage buffer||PBS, pH 7.6, with 1% BSA|
|Contains||<0.1% sodium azide|
|Storage Conditions||4° C, do not freeze|
|Tested Applications||Dilution *|
|Immunohistochemistry (Paraffin) (IHC (P))||1:50|
Heat-mediated antigen retrieval is recommended prior to staining, using a 10mM citrate buffer, pH 6.0, for 10 minutes followed by cooling at room temperature for 20 min. Following antigen retrieval, incubate samples with primary antibody for 10 min at room temperature. A suggested positive control is breast, colon or ovarian carcinoma.
The c-Met oncogene was originally isolated from a chemical carcinogen-treated human osteogenic sarcoma cell line by transfection analysis in NIH/3T3 cells. The Met proto-oncogene product was identified as a trans-membrane receptor-like protein with tyrosine kinase activity that is expressed in many tissues. The c-Met gene product has been identified as the cell surface receptor for hepatocyte growth factor, a plasminogen-like protein thought to be a humoral mediator of liver regeneration.
IP-MS enrichment of MET (LFQ intensity): MET was enriched 630-fold from BT549 lysate compared to background proteins, using the optimized IP-MS workflow with Pierce MS-Compatible Magnetic IP Kit protein A/G (Part No. 90409) and c-MET antibody (Part No. PA5-32357). The STRING database (www.string-db.org) was used to identify the protein interactor list. See more information on IP-MS verification of antibody selectivity. IP-MS validation info.
AUTS9; c-Met; hepatocyte growth factor receptor; HGF receptor; HGF/SF receptor; HGFR; met proto-oncogene tyrosine kinase; oncogene MET; proto-oncogene c-Met; RCCP2; scatter factor receptor; SF receptor; tyrosine-protein kinase Met
AUTS9; c-Met; DFNB97; HGFR; MET; RCCP2